FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2953022690> ?p ?o ?g. }

• W2953022690 abstract "Background S1P mediates a number of immune processes including the egress of lymphocytes from lymphoid organs via stimulation of the S1P subtype 1 receptor (S1P1R). S1P1R inhibition has the potential to suppress abnormal immune responses and modulate autoimmune inflammatory diseases.1 BMS-986166, a novel, selective partial agonist of S1P1R, which is phosphorylated in vivo to its pharmacologically active form, BMT-121795, may have utility for the treatment of autoimmune and/or inflammatory diseases. Objectives To investigate safety, pharmacokinetics (PK), and pharmacodynamics (PD) of BMS-986166 in single- and multiple-ascending dose (SAD/MAD) placebo (PBO)-controlled studies in healthy participants. Methods SAD study (NCT02790125): BMS-986166 was administered as a single dose of 0.75, 2.0, or 5.0 mg (n=10/group; 4:1 ratio of BMS-986166:PBO); a series of upwardly titrated single daily doses of 0.25, 0.5, 0.75, 1.0, then 1.5 mg over 14 days (n=16; 3:1 ratio); or as a single 2.0-mg dose in participants who were fed, fasted, or administered famotidine prior to dosing (n=8/group). MAD study (NCT03038711): BMS-986166 was administered as once-daily doses of 0.25 (n=12; 2:1 ratio), and 0.75 or 1.5 mg (n=10/dose; 4:1 ratio), for 28 days. Safety, PK, and PD (absolute lymphocyte count [ALC]) were assessed. Cardiac safety was assessed by continuous cardiac monitoring and at intervals by 12-lead electrocardiogram. Results 70 (60 BMS-986166, 10 PBO; mean [standard deviation (SD)] age: 32.8 [8.5] years) and 32 (24 BMS-986166, 8 PBO; mean [SD] age: 35.8 [8.6] years) participants were randomised to dosing in the SAD and MAD studies, respectively. Participants were predominantly male. Mean (SD) body mass index was 26.8 (2.9) and 27.2 (2.5) kg/m2, respectively. Multiple oral doses of BMS-986166 up to 1.5 mg daily for 28 days were generally well tolerated, and all treatment-related adverse events were mild (Grade 1). In the MAD (Figure 1) and SAD studies, a clinically insignificant, dose-related decrease in mean hourly heart rate (HR) was observed following administration of BMS-986166 compared with PBO, based on a time-matched analysis of nominal hourly HR data from continuous cardiac monitoring over 72 hours post dose. Compared with participants receiving PBO, a mean decrease from baseline in hourly HR was apparent for participants in the 2 higher dose panels (2.0 mg, 5.0 mg) in the SAD study. In the SAD study, the largest decreases in PBO-corrected, time-matched, nadir hourly HR were –0.29, –6.38, and –8.37 bpm for the 0.75, 2.0, and 5.0 mg dose panels, respectively. Similarly, in the MAD study, these numbers were –0.83, –3.46, and –5.54 bpm at the 0.25, 0.75, and 1.5 mg dose levels, respectively. Increases in systemic plasma exposure (maximum concentration and area under the curve from time 0–24 hours) of BMS-986166 and its active metabolite BMT-121795 were approximately proportional to dose increases over the range of 0.75–5 mg with single doses, and of 0.25–1.5 mg on Days 1, 14, and 28 with multiple doses. Decreases in percent change from baseline in ALC with multiple doses of BMS-986166 vs PBO were dose-related over the 28-day treatment period. Between Day 0 and 35, median (range) nadir in lymphocyte reductions were 53.7% (31.7–55.9%), 75.9% (63.3–85.8%), and 81.9% (37.9–92.2%) at 0.25, 0.75, and 1.5 mg BMS-986166 dose levels, respectively. Recovery of ALC levels began 14, 14–21, and 7 days after the last dose of 0.25, 0.75, and 1.5 mg, respectively, on Day 28. Conclusion In healthy participants, multiple daily doses of BMS-986166 in the range of 0.25–1.5 mg were well tolerated, with no clinically relevant lowering of HR. PK were linear and decreases in ALC were dose related. Reference [1] Urbano M, et al. Bioorg Med Chem Lett2013;23:6377–89 Acknowledgement Professional medical writing: Lola Parfitt, MRes (Caudex); funding: Bristol-Myers Squibb Disclosure of Interests Shalabh Singhal Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, Ihab Girgis Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, Jenny Xie Employee of: Bristol-Myers Squibb, Santanu Dutta Employee of: Bristol-Myers Squibb, Diane Shevell Shareholder of: Merck, Employee of: Bristol-Myers Squibb, John Throup Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb" @default.
• W2953022690 created "2019-06-27" @default.
• W2953022690 creator A5020311464 @default.
• W2953022690 creator A5021964558 @default.
• W2953022690 creator A5057771700 @default.
• W2953022690 creator A5078933052 @default.
• W2953022690 creator A5083502971 @default.
• W2953022690 creator A5024778802 @default.
• W2953022690 date "2019-06-01" @default.
• W2953022690 modified "2023-10-12" @default.
• W2953022690 title "THU0190 THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF BMS-986166, A NOVEL, SELECTIVE, PARTIAL AGONIST OF THE SPHINGOSINE-1-PHOSPHATE (S1P) SUBTYPE 1 RECEPTOR IN HEALTHY PARTICIPANTS" @default.
• W2953022690 doi "https://doi.org/10.1136/annrheumdis-2019-eular.1967" @default.
• W2953022690 hasPublicationYear "2019" @default.
• W2953022690 type Work @default.
• W2953022690 sameAs 2953022690 @default.
• W2953022690 citedByCount "1" @default.
• W2953022690 countsByYear W29530226902020 @default.
• W2953022690 crossrefType "proceedings-article" @default.
• W2953022690 hasAuthorship W2953022690A5020311464 @default.
• W2953022690 hasAuthorship W2953022690A5021964558 @default.
• W2953022690 hasAuthorship W2953022690A5024778802 @default.
• W2953022690 hasAuthorship W2953022690A5057771700 @default.
• W2953022690 hasAuthorship W2953022690A5078933052 @default.
• W2953022690 hasAuthorship W2953022690A5083502971 @default.
• W2953022690 hasBestOaLocation W29530226901 @default.
• W2953022690 hasConcept C111113717 @default.
• W2953022690 hasConcept C112705442 @default.
• W2953022690 hasConcept C126322002 @default.
• W2953022690 hasConcept C170493617 @default.
• W2953022690 hasConcept C2776549689 @default.
• W2953022690 hasConcept C2776596873 @default.
• W2953022690 hasConcept C2778703144 @default.
• W2953022690 hasConcept C2778938600 @default.
• W2953022690 hasConcept C58732023 @default.
• W2953022690 hasConcept C71924100 @default.
• W2953022690 hasConcept C98274493 @default.
• W2953022690 hasConceptScore W2953022690C111113717 @default.
• W2953022690 hasConceptScore W2953022690C112705442 @default.
• W2953022690 hasConceptScore W2953022690C126322002 @default.
• W2953022690 hasConceptScore W2953022690C170493617 @default.
• W2953022690 hasConceptScore W2953022690C2776549689 @default.
• W2953022690 hasConceptScore W2953022690C2776596873 @default.
• W2953022690 hasConceptScore W2953022690C2778703144 @default.
• W2953022690 hasConceptScore W2953022690C2778938600 @default.
• W2953022690 hasConceptScore W2953022690C58732023 @default.
• W2953022690 hasConceptScore W2953022690C71924100 @default.
• W2953022690 hasConceptScore W2953022690C98274493 @default.
• W2953022690 hasLocation W29530226901 @default.
• W2953022690 hasOpenAccess W2953022690 @default.
• W2953022690 hasPrimaryLocation W29530226901 @default.
• W2953022690 hasRelatedWork W1969026706 @default.
• W2953022690 hasRelatedWork W1977402941 @default.
• W2953022690 hasRelatedWork W2016111743 @default.
• W2953022690 hasRelatedWork W2105624539 @default.
• W2953022690 hasRelatedWork W2322218480 @default.
• W2953022690 hasRelatedWork W2326375399 @default.
• W2953022690 hasRelatedWork W2327999816 @default.
• W2953022690 hasRelatedWork W2503389107 @default.
• W2953022690 hasRelatedWork W2550037444 @default.
• W2953022690 hasRelatedWork W2567003761 @default.
• W2953022690 hasRelatedWork W2807925291 @default.
• W2953022690 hasRelatedWork W2898443052 @default.
• W2953022690 hasRelatedWork W2947762727 @default.
• W2953022690 hasRelatedWork W2948056808 @default.
• W2953022690 hasRelatedWork W2948431132 @default.
• W2953022690 hasRelatedWork W2992595410 @default.
• W2953022690 hasRelatedWork W2994872638 @default.
• W2953022690 hasRelatedWork W3111497338 @default.
• W2953022690 hasRelatedWork W3176697175 @default.
• W2953022690 hasRelatedWork W3177137789 @default.
• W2953022690 isParatext "false" @default.
• W2953022690 isRetracted "false" @default.
• W2953022690 magId "2953022690" @default.
• W2953022690 workType "article" @default.